Inositol Comestible Units for ASD Symptom Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering high doses of inositol to patients, particularly children, are inefficient and often unpalatable, leading to difficulties in treatment adherence and effectiveness in managing symptoms associated with Autistic Spectrum Disorder (ASD) and other psychiatric or neurological conditions.
Innovation Solution
Administering therapeutically effective amounts of inositol in a plurality of comestible units, such as cookies, which serve as both a therapeutic agent and a sugar substitute, allowing for precise dosing and improved patient compliance, potentially combined with an alpha-2 adrenergic agonist in an extended release dosage form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of inositol are administered in traditional dosage forms, then therapeutic effectiveness is improved, but patient compliance and ease of administration deteriorate
Solution Approach 1:
The patent divides the total inositol dose into multiple discrete dosage units (e.g., multiple cookies or food items), each containing a specific amount of inositol. This segmentation allows patients to consume the total therapeutic dose through multiple small, palatable units rather than a single large, unpalatable dose, thereby improving compliance while maintaining effectiveness
Solution Approach 2:
The patent uses food items (such as cookies, cakes, or other comestibles) as an intermediary vehicle to deliver inositol. This intermediary masks the potentially unpleasant taste or texture of high-dose inositol, making administration more acceptable to patients, particularly children, while ensuring the full therapeutic dose is delivered
2Ease of operation
If inositol is used as a sugar substitute in comestible units, then patient compliance is improved, but dosing precision may deteriorate
Solution Approach 1:
The patent carefully controls the concentration of inositol in the comestible units to balance two functions: providing enough sweetness to improve compliance and delivering a precise therapeutic dose. By adjusting the inositol concentration parameter within specific ranges, the patent achieves both palatability and dosing accuracy
Solution Approach 2:
The patent replaces traditional mechanical dosing methods (such as measuring spoons or capsules) with a pre-formulated comestible unit where the inositol dose is integrated into the food matrix. This substitution ensures consistent dosing through manufacturing control rather than manual measurement, improving both precision and compliance
Data Source
AI summary
A method for treating a patient having one or more of anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability, or otherwise requiring a calming effect, is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol.